CLL
MCID: LKM071
MIFTS: 75

Leukemia, Chronic Lymphocytic (CLL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leukemia, Chronic Lymphocytic

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic 57 73 36 38
Chronic Lymphocytic Leukemia 11 19 75 41 14 16 71
B-Cell Chronic Lymphocytic Leukemia 11 58 73 28 5
Cll 57 11 73
B-Cell Chronic Lymphoid Leukemia 11 58
Chronic Lymphocytic Leukaemia 11 14
Chronic Lymphatic Leukemia 11 73
Lymphoplasmacytic Leukemia 11 71
Small Lymphocytic Lymphoma 58 71
Leukemia, Lymphocytic, Chronic, B-Cell 43
B-Cell Chronic Lymphocytic Leukaemia 11
B Cell Chronic Lymphocytic Leukemia 19
Chronic B-Cell Lymphocytic Leukemia 19
Leukemia, Lymphocytic, Chronic 19
Leukemia Lymphocytic Chronic 53
Leukemia, Chronic Lymphatic 57
Chronic Lymphatic Leukaemia 11
Lymphoplasmacytic Leukaemia 11
Lymphoma Small Lymphocytic 53
Chronic Lymphoid Leukemia 73
B-Cll 58

Characteristics:


Inheritance:

Leukemia, Chronic Lymphocytic: Autosomal dominant 57
B-Cell Chronic Lymphocytic Leukemia: Multigenic/multifactorial 58

Prevelance:

B-Cell Chronic Lymphocytic Leukemia: 1-5/10000 (Europe) 1-9/100000 (France) 58

Age Of Onset:

B-Cell Chronic Lymphocytic Leukemia: Adult 58

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:1040
OMIM® 57 151400
ICD9CM 34 204.1
MeSH 43 D015451
NCIt 49 C3163
SNOMED-CT 68 51092000
MESH via Orphanet 44 D015451
ICD10 via Orphanet 32 C91.1
UMLS via Orphanet 72 C0023434 C0855095 C1868683
Orphanet 58 ORPHA67038
MedGen 40 C0023434
SNOMED-CT via HPO 69 277473004 92814006
UMLS 71 C0023434 C0855095 C2854089

Summaries for Leukemia, Chronic Lymphocytic

MedlinePlus: 41 What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What is chronic lymphocytic leukemia (CLL)? Chronic lymphocytic leukemia (CLL) is a type of chronic leukemia. "Chronic" means that the leukemia usually gets worse slowly. In CLL, the bone marrow makes abnormal lymphocytes (a type of white blood cell). When the abnormal cells crowd out the healthy cells, it can lead to infection, anemia, and easy bleeding. The abnormal cells can also spread outside the blood to other parts of the body. CLL is one of the most common types of leukemia in adults. It often occurs during or after middle age. It is rare in children. What causes chronic lymphocytic leukemia (CLL)? CLL happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown, so it's hard to predict who might get CLL. There are a few factors that might raise your risk. Who is at risk for chronic lymphocytic leukemia (CLL)? It is hard to predict who will get CLL. There are a few factors that could raise your risk: Age - your risk goes up as you get older. Most people who are diagnosed with CLL are over 50. Family history of CLL and other blood and bone marrow diseases Racial/ethnic group - CLL is more common in whites than in people from other racial or ethnic groups Exposure to certain chemicals, including Agent Orange, a chemical that was used in the Vietnam War What are the symptoms of chronic lymphocytic leukemia (CLL)? In the beginning, CLL does not cause any symptoms. Later, you can have symptoms such as: Swollen lymph nodes - you may notice them as painless lumps in the neck, underarm, stomach, or groin Weakness or feeling tired Pain or a feeling of fullness below the ribs Fever and infection Easy bruising or bleeding Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Weight loss for no known reason Drenching night sweats How is chronic lymphocytic leukemia (CLL) diagnosed? Your health care provider may use many tools to diagnose CLL: A physical exam A medical history Blood tests, such as a complete blood count (CBC) with differential and blood chemistry tests. Blood chemistry tests measure different substances in the blood, including electrolytes, fats, proteins, glucose (sugar), and enzymes. Specific blood chemistry tests include a basic metabolic panel (BMP), a comprehensive metabolic panel (CMP), kidney function tests, liver function tests, and an electrolyte panel. Flow cytometry tests, which check for leukemia cells and identify which type of leukemia it is. The tests can be done on blood, bone marrow, or other tissue. Genetic tests to look for gene and chromosome changes If you are diagnosed with CLL, you may have additional tests to see whether the cancer has spread. These include imaging tests and bone marrow tests. What are the treatments for chronic lymphocytic leukemia (CLL)? Treatments for CLL include: Watchful waiting, which means that you don't get treatment right away. Your health care provider regularly checks to see if your signs or symptoms appear or change. Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Chemotherapy Radiation therapy Immunotherapy Chemotherapy with bone marrow or stem cell transplant The goals of treatment are to slow the growth of the leukemia cells and to give you long periods of remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared. The CLL may come back after remission, and you may need more treatment. NIH: National Cancer Institute

MalaCards based summary: Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to richter's syndrome and chronic lymphocytic leukemia/small lymphocytic lymphoma, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic is TP53 (Tumor Protein P53), and among its related pathways/superpathways are miRNA regulation of DNA damage response and DNA damage response (only ATM dependent). The drugs Ofatumumab and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

Orphanet: 58 B-cell chronic lymphocytic leukemia (B-CLL) is a type of B-cell non-Hodgkin lymphoma (see this term), and the most common form of leukemia in Western countries, affecting elderly adults (mean age of 67 and 72 years) with a slight male predominance (1.7:1), and characterized by a highly variable clinical presentation that can include asymptomatic disease or non-specific B-symptoms such as unintentional weight loss, severe fatigue, fever (without evidence of infection), and night sweats as well as cervical lymphadenopathy, splenomegaly and frequent infections. Some patients can also develop autoimmune complications such as autoimmune hemolytic anemia or immune thrombocytopenia (see these terms). The clinical course is extremely heterogeneous with survival ranging from a few months to several decades.

GARD: 19 Chronic lymphocytic leukemia (CLL) is a type of cancer of the white blood cells (lymphocytes). Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and/or frequent infections. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. The underlying cause is thought to be a combination of genetic and other unknown factors. It usually occurs in people with no family history of the condition, but familial cases have been reported. CLL is diagnosed based on the symptoms and various blood tests.

OMIM®: 57 Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: 73 A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Disease Ontology: 11 A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

Wikipedia: 75 Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Related Diseases for Leukemia, Chronic Lymphocytic

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1342)
# Related Disease Score Top Affiliating Genes
1 richter's syndrome 33.1 TP53 RPS15 ATM
2 chronic lymphocytic leukemia/small lymphocytic lymphoma 32.9 TP53 MIR15A CCND1
3 lung cancer 32.4 TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR29A
4 burkitt lymphoma 32.4 TP53COR1 TP53 NEAT1 MIR29A MIR145 MIR143
5 melanoma 32.2 TP53 POT1 MIR34A MIR181A2 MIR15A MIR107
6 lymphoma, non-hodgkin, familial 32.1 TP53 MIR424 MIR34A MIR15A MIR145 MIR143
7 renal cell carcinoma, nonpapillary 32.1 TP53 MIR424 MIR34A MIR15A MIR145 MIR143
8 peripheral nervous system disease 32.0 TP53 MIR34A MIR29A MIR145 MIR143 CCND1
9 leukemia, acute myeloid 31.9 TP53 MIR424 MIR34A MIR29A MIR181A2 MIR145
10 connective tissue disease 31.9 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
11 esophageal cancer 31.8 TP53 MIR424 MIR34A MIR29A MIR145 MIR143
12 mantle cell lymphoma 31.8 TP53 MIR16-1 IKZF3 CCND1 ATM
13 lymphatic system disease 31.8 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
14 cervical cancer 31.7 TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR16-1
15 diffuse large b-cell lymphoma 31.7 MIR15A MIR145 MIR143 MIR106B
16 prostate cancer 31.6 TP53COR1 TP53 NEAT1 MIR34A MIR29A MIR16-1
17 kidney cancer 31.6 TP53 MIR424 MIR29A MIR15A MIR145 MIR106B
18 myeloma, multiple 31.6 TP53 MIR181A2 MIR15A MIR145 MIR106B CCND1
19 nervous system disease 31.6 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
20 chromosome 13q14 deletion syndrome 31.5 TP53 MIR15A ATM
21 prolymphocytic leukemia 31.5 TP53 CCND1 ATM
22 gastric cancer 31.5 TP53COR1 TP53 NEAT1 MIR34A MIR16-1 MIR15A
23 ovarian cancer 31.5 TP53 NEAT1 MIR424 MIR34A MIR29A MIR145
24 hepatocellular carcinoma 31.5 TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR29A
25 colorectal cancer 31.5 TP53COR1 TP53 NEAT1 MIR424 MIR34A MIR29A
26 rectum cancer 31.4 TP53 MIR424 MIR29A MIR145 MIR143
27 hematologic cancer 31.4 MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145
28 larynx cancer 31.4 TP53 MIR145 MIR143 MIR106B CCND1
29 colonic benign neoplasm 31.4 TP53 MIR15A MIR145 MIR143 CCND1 ATM
30 central nervous system disease 31.4 MIR34A MIR29A MIR15A MIR145 MIR143 MIR106B
31 brain cancer 31.4 TP53 MIR34A MIR145 MIR143 MIR106B
32 gastrointestinal system disease 31.3 MIR424 MIR34A MIR29A MIR15A MIR145 MIR143
33 laryngeal benign neoplasm 31.3 TP53 MIR106B CCND1
34 oral squamous cell carcinoma 31.2 NEAT1 MIR424 MIR34A MIR29A MIR145 MIR143
35 rectal benign neoplasm 31.2 TP53 MIR145 MIR143
36 gallbladder disease 31.2 TP53 MIR145 MIR143 CCND1
37 central nervous system cancer 31.2 TP53 MIR34A MIR15A MIR145 MIR143 MIR106B
38 colorectal adenocarcinoma 31.2 TP53 MIR29A MIR145 MIR143 CCND1
39 glioma 31.1 TP53COR1 TP53 NEAT1 MIR34A MIR181A2 MIR15A
40 type 2 diabetes mellitus 31.0 TP53 MIR34A MIR29A MIR145 MIR143 MIR106B
41 esophagus adenocarcinoma 31.0 TP53 MIR145 MIR143 CCND1
42 nasopharyngeal carcinoma 31.0 TP53 NEAT1 MIR145 MIR143 CCND1
43 bone marrow cancer 31.0 TP53 MIR34A MIR145 CCND1
44 melanoma, cutaneous malignant 1 31.0 TP53 POT1 CCND1 ATM
45 tongue carcinoma 30.9 TP53 MIR15A MIR143 CCND1
46 squamous cell carcinoma, head and neck 30.9 TP53 MIR424 MIR15A MIR145 MIR143 MIR106B
47 dyskeratosis congenita 30.9 TP53 RPS15 POT1 ATM
48 endometriosis 30.9 TP53 MIR424 MIR145 MIR143
49 lung cancer susceptibility 3 30.8 TP53 MIR15A MIR145 MIR143 MIR106B CCND1
50 high grade glioma 30.7 TP53COR1 TP53 NEAT1 MIR145 ATM

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Acute Cystitis
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bronchitis Chronic Leukemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:



Diseases related to Leukemia, Chronic Lymphocytic

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

Human phenotypes related to Leukemia, Chronic Lymphocytic:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cellular immunodeficiency 30 HP:0005374
2 chronic lymphatic leukemia 30 HP:0005550

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity

Clinical features from OMIM®:

151400 (Updated 08-Dec-2022)

UMLS symptoms related to Leukemia, Chronic Lymphocytic:


fatigue; angina pectoris; chest pain; edema

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofatumumab Approved Phase 4 679818-59-8
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Acalabrutinib Approved, Investigational Phase 4 1420477-60-6 71226663 71226662
4
Chlorambucil Approved Phase 4 305-03-3 2708
5
Epoetin Alfa Phase 4
6 Hematinics Phase 4
7 Chrysarobin Phase 4
8
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
9
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
10
Arsenic trioxide Approved, Investigational Phase 3 1327-53-3 518740
11
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
12
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
13
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
14
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
15
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
16
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
17
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704
18
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
19
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
20
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
21
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
22
Pancrelipase Approved, Investigational Phase 3 53608-75-6 8519
23
Fludarabine Approved Phase 2, Phase 3 75607-67-9, 21679-14-1 30751 657237
24
Lenograstim Approved, Investigational Phase 3 135968-09-1
25
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
28 Antimetabolites Phase 3
29 Antiviral Agents Phase 3
30 Anti-Infective Agents Phase 3
31 Dermatologic Agents Phase 3
32 Anti-Bacterial Agents Phase 3
33 Antimitotic Agents Phase 3
34 Tubulin Modulators Phase 3
35 Antibiotics, Antitubercular Phase 3
36 Liposomal doxorubicin Phase 3
37 Cyclosporins Phase 3
38 Antifungal Agents Phase 3
39 Ferric Oxide, Saccharated Phase 3
40 Folic Acid Antagonists Phase 3
41 Folate Phase 3
42 Vitamin B9 Phase 3
43 Vitamin B Complex Phase 3
44 Caseins Phase 2, Phase 3
45
Triamcinolone hexacetonide Phase 3
46
Triamcinolone diacetate Phase 3
47
Triamcinolone Acetonide Phase 3 6436
48 Liver Extracts Phase 3
49 Immunoglobulin G Phase 3
50 Paraproteins Phase 3

Interventional clinical trials:

(show top 50) (show all 1467)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
3 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
4 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
5 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
6 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
7 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
8 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Active, not recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
9 Long Term Effect on Immune Response After Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukemia and Evaluation of the Effect of Revaccination Active, not recruiting NCT05316831 Phase 4
10 A Prospective, Multi-centre, Phase IV Clinical Trial to Assess the Safety and Efficacy of Acalabrutinib Capsules in Indian Adult Patients With Chronic Lymphocytic Leukaemia and Relapsed and Refractory Mantle Cell Lymphoma Active, not recruiting NCT04930536 Phase 4 Acalabrutinib capsule
11 Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens Not yet recruiting NCT04790045 Phase 4 Venetoclax
12 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
13 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
14 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
15 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Unknown status NCT02991638 Phase 3 Ibrutinib
16 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
17 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
18 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
19 A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Unknown status NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
20 A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL Unknown status NCT02475681 Phase 3 Acalabrutinib;Obinutuzumab;Chlorambucil
21 A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
22 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
23 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Unknown status NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
24 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
25 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
26 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
27 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Completed NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
28 Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO Completed NCT00645606 Phase 3
29 Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) Completed NCT02756611 Phase 3 Venetoclax
30 A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
31 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial) Completed NCT00774345 Phase 3 Lenalidomide;Placebo
32 A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed NCT02301156 Phase 3 Ublituximab;Ibrutinib
33 A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity Completed NCT03730129 Phase 2, Phase 3 Hizentra
34 A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
35 A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab Completed NCT02005471 Phase 3 Bendamustine;Venetoclax;Rituximab
36 Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) Completed NCT02980731 Phase 3 Venetoclax
37 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
38 A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT02264574 Phase 3 Ibrutinib;Obinutuzumab;Chlorambucil
39 A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 Cladribine;Cyclophosphamide;Rituximab
40 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO) Completed NCT02004522 Phase 3 Duvelisib;Ofatumumab
41 Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
42 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
43 A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00086580 Phase 3
44 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
45 Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT00564512 Phase 3 cyclophosphamide;fludarabine
46 Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00003764 Phase 3 cyclophosphamide;fludarabine phosphate
47 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
48 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
49 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
50 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Leukemia, Chronic Lymphocytic

Genetic tests related to Leukemia, Chronic Lymphocytic:

# Genetic test Affiliating Genes
1 B-Cell Chronic Lymphocytic Leukemia 28

Anatomical Context for Leukemia, Chronic Lymphocytic

Organs/tissues related to Leukemia, Chronic Lymphocytic:

MalaCards : Bone Marrow, Bone, T Cells, Lymph Node, B Cells, Spleen, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Chronic Lymphocytic

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 24922)
# Title Authors PMID Year
1
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. 62 46 57
16251535 2005
2
miR-15 and miR-16 induce apoptosis by targeting BCL2. 62 46 57
16166262 2005
3
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. 53 62 57
12595313 2003
4
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 53 62 57
12724482 2003
5
Non-coding recurrent mutations in chronic lymphocytic leukaemia. 62 57
26200345 2015
6
Mutations driving CLL and their evolution in progression and relapse. 62 57
26466571 2015
7
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. 62 5
24869598 2014
8
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. 62 57
23770605 2013
9
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. 62 57
22158541 2011
10
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. 62 57
22150006 2011
11
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. 62 57
21642962 2011
12
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. 62 57
21131588 2011
13
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. 53 62 46
19717645 2009
14
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. 62 57
17047154 2007
15
Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia. 62 57
17116127 2007
16
HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. 62 57
15931393 2005
17
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. 62 57
15161669 2004
18
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. 62 57
14973191 2004
19
Cytogenetic findings in familial B-cell chronic lymphocytic leukemia: a report of two cases in a family. 62 57
12781453 2003
20
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 62 57
12434020 2002
21
Hereditary chronic lymphocytic leukemia: an extended family study and literature review. 62 57
12407690 2002
22
A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. 62 57
11943260 2002
23
Genomic aberrations and survival in chronic lymphocytic leukemia. 62 57
11136261 2000
24
Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. 62 57
11090088 2000
25
Anticipation in familial chronic lymphocytic leukemia. 62 57
10364544 1999
26
Anticipation in familial leukemia. 62 57
8900225 1996
27
Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. 62 57
3122218 1987
28
Human heavy-chain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia. 62 57
3120193 1987
29
Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. 62 57
3923362 1985
30
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. 62 57
6610211 1984
31
Familial chronic lymphocytic leukemia. 62 57
6418939 1983
32
Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. 62 57
7001171 1980
33
Lymphocyte studies in familial chronic lymphatic leukemia. 62 57
637060 1978
34
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. 62 57
818930 1976
35
Familial chronic lymphocytic leukemia. 62 57
4184386 1969
36
An abnormal chromosome in chronic lymphocytic leukaemia. 62 57
13951305 1962
37
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
38
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
39
Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. 62 46
21130495 2011
40
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. 62 46
20566844 2010
41
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. 62 46
20089965 2010
42
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. 62 46
19692702 2009
43
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. 62 46
19144983 2009
44
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. 62 46
19096009 2009
45
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. 62 46
18818704 2009
46
MiR-15a and miR-16-1 cluster functions in human leukemia. 62 46
18362358 2008
47
Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. 62 46
17989717 2008
48
Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. 5
18060073 2007
49
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. 62 46
17707831 2007
50
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. 62 46
17327404 2007

Variations for Leukemia, Chronic Lymphocytic

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

5 (show top 50) (show all 106)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.-19_*21del (p.Met1fs) DEL Pathogenic
1174011 GRCh37: 17:7572906-7579931
GRCh38: 17:7669588-7676613
2 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Pathogenic
127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
3 TP53 NM_000546.6(TP53):c.743G>T (p.Arg248Leu) SNV Likely Pathogenic
230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
4 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
5 TP53 NM_000546.6(TP53):c.817C>A (p.Arg273Ser) SNV Likely Pathogenic
376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
6 TP53 NM_000546.6(TP53):c.841G>T (p.Asp281Tyr) SNV Likely Pathogenic
376585 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
7 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn) SNV Likely Pathogenic
376286 rs121913365 GRCh37: 7:140453132-140453132
GRCh38: 7:140753332-140753332
8 SF3B1 NM_012433.4(SF3B1):c.2225G>A (p.Gly742Asp) SNV Likely Pathogenic
376530 rs755415626 GRCh37: 2:198266611-198266611
GRCh38: 2:197401887-197401887
9 PLCG2 NM_002661.5(PLCG2):c.2535A>C (p.Leu845Phe) SNV Likely Pathogenic
376214 rs1057519832 GRCh37: 16:81962183-81962183
GRCh38: 16:81928578-81928578
10 SF3B1 NM_012433.4(SF3B1):c.1874G>A (p.Arg625His) SNV Likely Pathogenic
376534 rs1057519961 GRCh37: 2:198267483-198267483
GRCh38: 2:197402759-197402759
11 SF3B2 NM_006842.3(SF3B2):c.1997A>C (p.His666Pro) SNV Likely Pathogenic
376531 rs1057519959 GRCh37: 11:65830499-65830499
GRCh38: 11:66063028-66063028
12 PTPN11 NM_002834.5(PTPN11):c.215C>A (p.Ala72Asp) SNV Likely Pathogenic
376511 rs121918454 GRCh37: 12:112888199-112888199
GRCh38: 12:112450395-112450395
13 SF3B1 NM_012433.4(SF3B1):c.1873C>T (p.Arg625Cys) SNV Likely Pathogenic
376535 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
14 SF3B1 NM_012433.4(SF3B1):c.1996A>G (p.Lys666Glu) SNV Likely Pathogenic
376008 rs754688962 GRCh37: 2:198267361-198267361
GRCh38: 2:197402637-197402637
15 MYD88 NM_002468.5(MYD88):c.755T>C (p.Leu252Pro) SNV Likely Pathogenic
37055 rs387907272 GRCh37: 3:38182641-38182641
GRCh38: 3:38141150-38141150
16 XPO1 NM_003400.4(XPO1):c.1712A>T (p.Glu571Val) SNV Likely Pathogenic
376696 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
17 XPO1 NM_003400.4(XPO1):c.1712A>C (p.Glu571Ala) SNV Likely Pathogenic
376697 rs1057520010 GRCh37: 2:61719471-61719471
GRCh38: 2:61492336-61492336
18 PLCG2 NM_002661.5(PLCG2):c.2535A>T (p.Leu845Phe) SNV Likely Pathogenic
376215 rs1057519832 GRCh37: 16:81962183-81962183
GRCh38: 16:81928578-81928578
19 SF3B1 NM_012433.4(SF3B1):c.1873C>G (p.Arg625Gly) SNV Likely Pathogenic
376536 rs775623976 GRCh37: 2:198267484-198267484
GRCh38: 2:197402760-197402760
20 PLCG2 NM_002661.5(PLCG2):c.1993C>T (p.Arg665Trp) SNV Likely Pathogenic
376213 rs1057519831 GRCh37: 16:81946260-81946260
GRCh38: 16:81912655-81912655
21 XPO1 NM_003400.4(XPO1):c.1711G>A (p.Glu571Lys) SNV Likely Pathogenic
376695 rs1057520009 GRCh37: 2:61719472-61719472
GRCh38: 2:61492337-61492337
22 SF3B1 NM_012433.4(SF3B1):c.1996A>C (p.Lys666Gln) SNV Likely Pathogenic
376532 rs754688962 GRCh37: 2:198267361-198267361
GRCh38: 2:197402637-197402637
23 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely Pathogenic
73058 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
24 TP53 NM_000546.6(TP53):c.641A>T (p.His214Leu) SNV Likely Pathogenic
376616 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
25 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely Pathogenic
13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
26 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely Pathogenic
12606 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
27 BRAF NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu) SNV Likely Pathogenic
13966 rs121913364 GRCh37: 7:140453134-140453134
GRCh38: 7:140753334-140753334
28 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
29 TP53 NM_000546.6(TP53):c.578A>G (p.His193Arg) SNV Likely Pathogenic
184979 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
30 TP53 NM_000546.6(TP53):c.724T>A (p.Cys242Ser) SNV Likely Pathogenic
376579 rs1057519982 GRCh37: 17:7577557-7577557
GRCh38: 17:7674239-7674239
31 TP53 NM_000546.6(TP53):c.578A>T (p.His193Leu) SNV Likely Pathogenic
185822 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
32 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
33 TP53 NM_000546.6(TP53):c.764T>A (p.Ile255Asn) SNV Likely Pathogenic
232289 rs876659675 GRCh37: 17:7577517-7577517
GRCh38: 17:7674199-7674199
34 TP53 NM_000546.6(TP53):c.818G>T (p.Arg273Leu) SNV Likely Pathogenic
376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
35 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
36 TP53 NM_000546.6(TP53):c.841G>A (p.Asp281Asn) SNV Likely Pathogenic
376586 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
37 TP53 NM_000546.6(TP53):c.577C>T (p.His193Tyr) SNV Likely Pathogenic
230256 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
38 TP53 NM_000546.6(TP53):c.742C>G (p.Arg248Gly) SNV Likely Pathogenic
376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
39 TP53 NM_000546.6(TP53):c.713G>C (p.Cys238Ser) SNV Likely Pathogenic
376575 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
40 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
41 TP53 NM_000546.6(TP53):c.725G>A (p.Cys242Tyr) SNV Likely Pathogenic
12354 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
42 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
43 TP53 NM_000546.6(TP53):c.584T>C (p.Ile195Thr) SNV Likely Pathogenic
216077 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
44 TP53 NM_000546.6(TP53):c.713G>A (p.Cys238Tyr) SNV Likely Pathogenic
182935 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
45 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely Pathogenic
245851 rs138729528 GRCh37: 17:7578407-7578407
GRCh38: 17:7675089-7675089
46 TP53 NM_000546.6(TP53):c.843C>G (p.Asp281Glu) SNV Likely Pathogenic
376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777
47 TP53 NM_000546.6(TP53):c.712T>G (p.Cys238Gly) SNV Likely Pathogenic
376577 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
48 PTPN11 NM_002834.5(PTPN11):c.215C>T (p.Ala72Val) SNV Likely Pathogenic
41443 rs121918454 GRCh37: 12:112888199-112888199
GRCh38: 12:112450395-112450395
49 TP53 NM_000546.6(TP53):c.725G>T (p.Cys242Phe) SNV Likely Pathogenic
376578 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
50 TP53 NM_000546.6(TP53):c.824G>C (p.Cys275Ser) SNV Likely Pathogenic
376583 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796

Copy number variations for Leukemia, Chronic Lymphocytic from CNVD:

6 (show top 50) (show all 1219)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14042 1 103366560 104230405 Loss Chronic lymphocytic leukemia
2 14895 1 110954839 111582296 Loss Chronic lymphocytic leukemia
3 14947 1 111421057 111642223 Loss Chronic lymphocytic leukemia
4 15456 1 115719205 117399077 Loss Chronic lymphocytic leukemia
5 17206 1 141510591 145121245 Deletion Chronic lymphocytic leukemia
6 17207 1 141510591 145121245 Loss Chronic lymphocytic leukemia
7 18527 1 146265358 148164994 Gain Chronic lymphocytic leukemia
8 19758 1 151208615 155645185 Gain Chronic lymphocytic leukemia
9 20025 1 152611898 157344161 Loss Chronic lymphocytic leukemia
10 21378 1 158336749 159355008 Loss Chronic lymphocytic leukemia
11 21384 1 158391645 159433573 Loss Chronic lymphocytic leukemia
12 21385 1 158391645 189498990 Loss Chronic lymphocytic leukemia
13 23023 1 170758115 170759115 Loss Chronic lymphocytic leukemia
14 23030 1 170822660 170823660 Gain Chronic lymphocytic leukemia
15 23626 1 172107770 172108770 Gain Chronic lymphocytic leukemia
16 24171 1 176708253 177307399 Gain Chronic lymphocytic leukemia
17 25274 1 186459864 186720923 Loss Chronic lymphocytic leukemia
18 25359 1 187890295 188217703 Loss Chronic lymphocytic leukemia
19 25435 1 189143434 189363313 Gain Chronic lymphocytic leukemia
20 25473 1 189804292 192389810 Gain Chronic lymphocytic leukemia
21 25685 1 193314169 193528753 Gain Chronic lymphocytic leukemia
22 26789 1 202768030 203457313 Loss Chronic lymphocytic leukemia
23 26818 1 203067017 205298659 Loss Chronic lymphocytic leukemia
24 26975 1 204424298 206588789 Loss Chronic lymphocytic leukemia
25 28076 1 218313329 220732423 Loss Chronic lymphocytic leukemia
26 28130 1 218942571 219164038 Loss Chronic lymphocytic leukemia
27 28133 1 218959043 244561923 Loss Chronic lymphocytic leukemia
28 28265 1 220678511 222112407 Gain Chronic lymphocytic leukemia
29 28321 1 221304071 221582122 Gain Chronic lymphocytic leukemia
30 28577 1 223594083 225234079 Loss Chronic lymphocytic leukemia
31 28643 1 224353010 225571533 Loss Chronic lymphocytic leukemia
32 28702 1 224857883 233411748 Loss Chronic lymphocytic leukemia
33 29066 1 227299711 227518155 Loss Chronic lymphocytic leukemia
34 29113 1 227696842 233631743 Loss Chronic lymphocytic leukemia
35 29265 1 229664393 229947546 Gain Chronic lymphocytic leukemia
36 29501 1 232707626 233302391 Loss Chronic lymphocytic leukemia
37 31053 1 24943712 26054939 Loss Chronic lymphocytic leukemia
38 31193 1 25985121 29490451 Deletion Chronic lymphocytic leukemia
39 31425 1 27504484 28494376 Loss Chronic lymphocytic leukemia
40 32443 1 36783544 38823237 Loss Chronic lymphocytic leukemia
41 33495 1 45606989 46307302 Gain Chronic lymphocytic leukemia
42 34016 1 51545765 53346467 Loss Chronic lymphocytic leukemia
43 34255 1 54029769 55100800 Loss Chronic lymphocytic leukemia
44 34911 1 57712092 58034742 Gain Chronic lymphocytic leukemia
45 35379 1 62697088 63142732 Loss Chronic lymphocytic leukemia
46 35406 1 63335974 63596958 Gain Chronic lymphocytic leukemia
47 35407 1 63335974 63641668 Gain Chronic lymphocytic leukemia
48 36497 1 76364563 76710672 Loss Chronic lymphocytic leukemia
49 36890 1 82341866 82576806 Loss Chronic lymphocytic leukemia
50 36895 1 82581235 82812961 Loss Chronic lymphocytic leukemia

Expression for Leukemia, Chronic Lymphocytic

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.

Pathways for Leukemia, Chronic Lymphocytic

GO Terms for Leukemia, Chronic Lymphocytic

Cellular components related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.62 NEAT1 MIR424 MIR29A MIR181A2 MIR16-1 MIR15A
2 extracellular vesicle GO:1903561 9.43 MIR34A MIR29A MIR16-1 MIR15A MIR107 MIR106B

Biological processes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 10.2 MIR106B MIR107 MIR143 MIR145 MIR15A MIR16-1
2 positive regulation of apoptotic process GO:0043065 10.15 TP53 MIR29A MIR16-1 MIR15A ATM
3 negative regulation of gene expression GO:0010629 9.99 TP53 MIR34A MIR29A MIR181A2 MIR106B
4 regulation of telomere maintenance via telomerase GO:0032210 9.88 POT1 ATM
5 negative regulation of inflammatory response GO:0050728 9.86 MIR181A2 MIR16-1 MIR15A MIR145
6 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.84 TP53 MIR16-1 MIR15A
7 negative regulation of protein kinase B signaling GO:0051898 9.79 MIR34A MIR29A MIR145
8 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 MIR29A MIR16-1 MIR15A
9 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.76 MIR16-1 MIR34A TP53
10 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 9.72 MIR424 MIR34A MIR15A
11 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.7 MIR424 MIR16-1 MIR15A
12 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR424 MIR34A MIR15A
13 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
14 positive regulation of connective tissue replacement GO:1905205 9.61 MIR34A MIR16-1
15 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.61 MIR15A MIR16-1 MIR424
16 aorta smooth muscle tissue morphogenesis GO:0060414 9.58 MIR143 MIR145
17 negative regulation of amyloid precursor protein catabolic process GO:1902992 9.57 MIR107 MIR29A
18 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR34A MIR16-1 MIR15A MIR107
19 negative regulation of angiogenesis GO:0016525 9.56 MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145
20 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 9.51 MIR424 MIR16-1
21 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
22 negative regulation of endothelial cell chemotaxis to vascular endothelial growth factor GO:1904858 9.4 MIR424 MIR16-1
23 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.37 MIR16-1 MIR15A
24 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143
25 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.17 MIR29A MIR181A2 MIR16-1 MIR15A MIR145 MIR107

Molecular functions related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 TP53 MIR424 MIR34A MIR29A MIR181A2 MIR16-1
2 mRNA base-pairing translational repressor activity GO:1903231 9.32 MIR424 MIR34A MIR29A MIR181A2 MIR16-1 MIR15A

Sources for Leukemia, Chronic Lymphocytic

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....